Edgar Filing: COVALENT GROUP INC

COVALENT GROUP, INC.--FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the quarterly period ended September 30, 2003.

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

for the transition period from to

Commission file number: 0-21145

COVALENT GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware

56-1668867

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)

One Glenhardie Corporate Center,

1275 Drummers Lane, Suite 100,

Wayne, Pennsylvania

19087

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: 610-975-9533

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨.

Indicate by check mark whether the registrant is an accelerated filer (as defined in rule 12(b)-2 of the Exchange Act). Yes ¨ No x.

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date: As of November 3, 2003 there were 13,070,051 shares of Covalent Group, Inc. common stock outstanding, par value $.001 per share, excluding 152,932 shares in treasury.

COVALENT GROUP, INC.

INDEX

			Page
PART I.	Financial Information

	Item 1.	Consolidated Financial Statements (unaudited)

		Consolidated balance sheets – September 30, 2003 and December 31, 2002	3

		Consolidated statements of operations – Three and nine months ended September 30, 2003 and 2002	4

		Consolidated statements of cash flows – Nine months ended September 30, 2003 and 2002	5

		Notes to consolidated financial statements	6

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

	Item 3.	Quantitative and Qualitative Disclosure about Market Risk	23

	Item 4.	Controls and Procedures	24

PART II.	Other Information

	Item 6.	Exhibits and Reports on Form 8-K	24

SIGNATURES			25

PART I. FINANCIAL INFORMATION

ITEM 1.

CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Covalent Group, Inc.

Consolidated Balance Sheets

(Unaudited)

	September 30, 2003			December 31, 2002
Assets
Current Assets
Cash and cash equivalents	$	2,282,840		$	2,121,439
Restricted cash		73,181			419,791
Accounts receivable		8,254,551			7,586,575
Prepaid expenses and other		1,308,190			380,404
Costs and estimated earnings in excess of related billings on uncompleted contracts		7,773,604			9,024,854

Total Current Assets		19,692,366			19,533,063

Property and Equipment, Net		2,105,411			1,281,149

Other Assets		22,186			22,265

Total Assets	$	21,819,963		$	20,836,477

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	2,770,300		$	2,755,520
Accrued expenses		133,213			403,735
Income tax payable		—			111,646
Obligations under capital leases		36,425			59,418
Billings in excess of related costs and estimated earnings on uncompleted contracts		1,392,403			1,817,697
Customer advances		4,408,756			3,612,856

Total Current Liabilities		8,741,097			8,760,872

Long Term Liabilities
Obligations under capital leases		101,704			2,907
Other liabilities		727,135			—
Deferred income tax		246,387			344,225

Total Long Term Liabilities		1,075,226			347,132

Total Liabilities		9,816,323			9,108,004

Stockholders’ Equity
Common stock, $.001 par value 25,000,000 shares authorized, 13,222,983 and 12,664,583 shares issued respectively		13,223			12,665
Additional paid-in capital		11,346,012			10,887,759
Retained earnings		1,012,729			852,021
Accumulated other comprehensive income		90,650			26,344

Less:		12,462,614			11,778,789
Treasury stock, at cost, 152,932 and 12,500 shares, respectively		(458,974	)		(50,316	)

Total Stockholders’ Equity		12,003,640			11,728,473

Total Liabilities and Stockholders’ Equity	$	21,819,963		$	20,836,477

See accompanying notes to the consolidated financial statements.

Covalent Group, Inc.

Consolidated Statements of Operations

(Unaudited)

	Three Months Ended September 30,					Nine Months Ended September 30,
	2003			2002		2003			2002
Net revenue	$	3,876,593		$	6,001,436	$	15,995,950		$	17,641,723
Reimbursement revenue		2,026,201			1,300,065		3,872,974			3,183,812

Total Revenue	$	5,902,794		$	7,301,501	$	19,868,924		$	20,825,535

Operating Expenses
Direct		3,434,767			4,236,848		11,207,737			10,705,092
Reimbursement out-of-pocket expenses		2,026,201			1,300,065		3,872,974			3,183,812
Selling, general and administrative		1,197,290			1,020,808		4,191,566			3,581,136
Depreciation and amortization		232,052			170,586		666,676			460,563

Total Operating Expenses		6,890,310			6,728,307		19,938,953			17,930,603

Income (Loss) from Operations		(987,516	)		573,194		(70,029	)		2,894,932

Net Interest Income		1,912			1,943		8,564			6,222

Income (Loss) before Income Taxes		(985,604	)		575,137		(61,465	)		2,901,154

Income Tax Provision (Benefit)		(593,320	)		195,000		(222,173	)		1,116,476

Net Income (Loss)	$	(392,284	)	$	380,137	$	160,708		$	1,784,678

Net Income (Loss) per Common Share

Basic:	$	(0.03	)	$	0.03	$	0.01		$	0.14
Diluted:	$	(0.03	)	$	0.03	$	0.01		$	0.13

Weighted Average Common and Common Equivalent Shares Outstanding
Basic		12,884,691			12,605,383		12,637,364			12,568,327
Diluted		12,884,691			13,075,539		12,966,815			13,222,161

See accompanying notes to the consolidated financial statements.

Covalent Group, Inc.

Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended September 30,
	2003			2002
Operating Activities:

Net income	$	160,708		$	1,784,678
Adjustments to reconcile net income to net cash provided (used) by operating activities:
Depreciation and amortization		666,676			460,563
Changes in assets and liabilities;
Restricted cash		346,610			459,951
Accounts receivable		(667,976	)		(3,779,846	)
Prepaid expenses and other		(927,786	)		(417,902	)
Costs and estimated earnings in excess of related billings on uncompleted contracts		1,251,250			(2,717,485	)
Other assets		79			2,964
Accounts payable		14,780			967,748
Accrued expenses		(270,522	)		(492,888	)
Income taxes payable		(111,646	)		(628,898	)
Deferred taxes		(97,838	)
Billings in excess of related costs and estimated earnings on uncompleted contracts		(425,294	)		1,473,542
Customer advances		795,900			1,056,523

Net Cash Provided by (Used) In Operating Activities		734,941			(1,831,050	)

Investing Activities:

Purchases of property and equipment		(763,803	)		(343,577	)

Net Cash Used In Investing Activities		(763,803	)		(343,577	)

Financing Activities:
Net repayments and borrowings under capital leases		75,804			(49,370	)
Treasury stock transactions		(408,658	)		—
Proceeds from exercise of stock options		458,811			369,349

Net Cash Provided By Financing Activities		125,957			319,979

Effect of Exchange Rate Changes on Cash and Cash Equivalents		64,306			(13	)

Net Increase (Decrease) In Cash and Cash Equivalents		161,401			(1,854,661	)

Cash and Cash Equivalents, Beginning of Period		2,121,439			3,454,543

Cash and Cash Equivalents, End of Period	$	2,282,840		$	1,599,882

See accompanying notes to the consolidated financial statements.

Covalent Group, Inc.

Notes to Consolidated Financial Statements

(Unaudited)

1.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The accompanying unaudited financial statements for the three and nine months ended September 30, 2003 and September 30, 2002 have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (primarily consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2003 may not necessarily be indicative of the results that may be expected for other quarters or for the year ending December 31, 2003. For further information, refer to the financial statements and footnotes thereto included in our Annual Report on Form 10-KSB for the year ended December 31, 2002.

Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Consolidation

The consolidated financial statements for the three and nine months ended September 30, 2003 and 2002 include our accounts and the accounts of our wholly-owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

Restricted Cash

We received advance payments from one of our clients as part of a long-term contract, which included a separate restricted cash account to be utilized for payment of investigator fees. As of September 30, 2003 and 2002, this restricted cash amount was $73 thousand and $192 thousand, respectively. This amount is also included in customer advances in the accompanying balance sheets.

Revenue Recognition

determine the percentage of the contract that is completed. This percentage is multiplied by the estimated total contract value to determine the amount of net revenue recognized. A formal project review process takes place quarterly although most projects are evaluated on an ongoing basis. Management reviews the estimated total direct costs on each contract to determine if estimated amounts are correct, and estimates are adjusted as needed. If we determine that a loss will result from the performance of a fixed-price contract, the entire amount of the estimated loss is charged against income in the period in which such determination is made. Because of the inherent uncertainties in estimating direct costs required to complete a project, particularly complex, multi-year studies, it is possible that the estimates used will change and could result in a material change to our estimates. Original estimates might also be changed due to changes in the scope of work. We attempt to negotiate contract amendments with the client to cover these services provided outside the terms of the original contract. There can be no assurance that the client will agree to the proposed amendments, and we ultimately bear the risk of cost overruns. For terminated studies, our contracts frequently entitle us to receive the costs of winding down the terminated project, as well as all fees earned by us up to the time of termination. Some contracts also entitle us to an early termination fee, usually in the form of a predetermined fee or percentage of revenue expected to be earned for completion of the project.

Costs and estimated earnings in excess of related billings on uncompleted contracts represents net revenue recognized to date that is currently unbillable to the client pursuant to contractual terms. In general, amounts become billable upon the achievement of milestones or in accordance with predetermined payment schedules set forth in the contracts with our clients. Billings in excess of related costs and estimated earnings on uncompleted contracts represent amounts billed in excess of net revenue recognized at the balance sheet date.

Reimbursable Out-of-Pocket Expenses

On behalf of our clients, we pay fees to investigators and other out-of-pocket costs for which we are reimbursed at cost, without mark-up or profit. Effective January 1, 2002, in connection with the required implementation of Financial Accounting Standards Board Emerging Issues Task Force Rule No. 01-14 (“EITF 01-14”), “Income Statement Characterization of Reimbursements Received for ‘Out-of-Pocket’ Expenses Incurred”, out-of-pocket costs are now included in Operating Expenses, while the reimbursements received are reported separately as Reimbursement Revenue in the Consolidated Statements of Operations.

As is customary in the industry, we exclude from revenue and expense in the Consolidated Statement of Operations fees paid to investigators and the associated reimbursement since we act as agent on behalf of our clients with regard to investigators. These investigator fees are not reflected in our Net Revenue, Reimbursement Revenue, Reimbursement Out-of-Pocket Expenses, and/or Direct Expenses. The amounts of these investigator fees were $2.4 million and $7.8 million for the three and nine months ended September 30, 2003, respectively. For the three and nine months ended September 30, 2002, investigator fees were $2.5 million and $6.2 million, respectively.

Stock Based Compensation

related interpretations. No stock-based compensation expense is reflected in net income as all options granted under the plan had an exercise price equal to the market value of the underlying common stock on the date of the grant. In addition to APB Opinion No. 25, we provide the disclosures required by SFAS No. 123 “Accounting for Stock-Based Compensation” and by SFAS No. 148 “Accounting for Stock-Based Compensation – Transition and Disclosure.” See Note 4.

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123, “Accounting for Stock-Based Compensation” to stock-based employee compensation:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2003			2002			2003			2002
Net Income (Loss) - as reported	$	(392,284	)	$	380,137		$	160,708		$	1,784,678

Deduct: Pro forma stock-based compensation expense determined under the fair value method, net of related tax effects		(133,888	)		(221,238	)		(366,948	)		(619,701	)

Pro forma Net Income (Loss)	$	(526,172	)	$	158,899		$	(206,240	)	$	1,164,977

Net Income (Loss) Per Share
Basic - as reported	$	(0.03	)	$	0.03		$	0.01		$	0.14
Basic - pro forma	$	(0.04	)	$	0.01		$	(0.02	)	$	0.09

Diluted - as reported	$	(0.03	)	$	0.03		$	0.01		$	0.13
Diluted - pro forma	$	(0.04	)	$	0.01		$	(0.02	)	$	0.09

Reclassifications

Certain prior year balances have been reclassified to conform to the current year presentation.

2.	RECENTLY ISSUED ACCOUNTING STANDARDS:

In June 2001, the FASB issued SFAS No. 143, “Accounting for Asset Retirement Obligations.” This Statement addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. This Statement requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. SFAS No. 143 is effective for financial statements issued for fiscal years beginning after June 15, 2002. Adoption of SFAS No. 143 did not have a material impact on our financial statements.

In July 2002, the FASB issued SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” SFAS No. 146 requires companies to recognize costs associated with exit or disposal activities when they are incurred rather than at the date of a commitment to an exit or disposal plan. Previous accounting guidance was provided by EITF No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring).” SFAS No. 146 replaces EITF No. 94-3 and is to be applied prospectively to exit or disposal activities initiated after December 31, 2002.

Adoption of SFAS No. 146 did not have a material impact on our financial statements.

In November 2002, the EITF finalized its tentative consensus on EITF Issue 00-21, “Revenue Arrangements with Multiple Deliverables”, which provides guidance on the timing and method of revenue recognition for sales arrangements that include the delivery of more than one product or service. EITF 00-21 is effective prospectively for arrangements entered into in fiscal periods beginning after June 15, 2003. Adoption of EITF Issue 00-21 did not have a material impact on our financial statements.

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure.” SFAS No. 148 amends SFAS No. 123 to provide for alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. SFAS No. 148 also requires disclosure of comparable information for all companies, regardless of whether they have adopted the fair value or intrinsic value method of accounting for stock-based employee compensation. SFAS No. 148 is effective for financial statements issued for fiscal years ending after December 15, 2002, and interim periods beginning after December 15, 2002. Adoption of SFAS No. 148 did not have a material impact on our financial statements, other than expanding our disclosures.

In January 2003, the FASB issued Interpretation No. 46, “Consolidation of Variable Interest Entities.” Interpretation No. 46 provides an interpretation of Accounting Research Bulletin No. 51, “Consolidated Financial Statements” with respect to the consolidation of variable interest entities. Interpretation No. 46 requires existing unconsolidated variable interest entities to be consolidated by their primary beneficiaries if the entities do not effectively disperse risks among the parties involved. Interpretation No. 46 applies immediately to variable interest entities created after January 31, 2003 and, for variable interest entities created before February 1, 2003, it becomes applicable for fiscal periods beginning after June 15, 2003. Adoption of Interpretation No. 46 is not expected to have a material impact on our financial statements.

In April 2003, the FASB issued SFAS No. 149, “Amendment of Statement 133 on Derivative Instruments and Hedging Activities.” SFAS No. 149 amends and clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts (collectively referred to as derivatives) and for hedging activities under SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003, except as stated below and for hedging relationships designated after June 30, 2003. The provisions of SFAS No. 149 that relate to Statement 133 Implementation Issues that have been effective for fiscal quarters that began prior to June 15, 2003, should continue to be applied in accordance with their respective effective dates. The Company has not entered into any derivative transactions and therefore this standard is not expected to have a material impact on our financial statements.

In May 2003, the FASB issued SFAS No. 150, “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity”, which establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. SFAS No. 150 requires that an issuer classify a financial instrument that is within its scope, which may have previously been reported as equity, as a liability (or an asset in some circumstances). This statement is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003, except for mandatory redeemable financial instruments of nonpublic companies. Adoption of SFAS No. 150 is not expected to have a material impact on our financial statements.

3.	EARNINGS PER SHARE

Earnings per share is calculated in accordance with SFAS No. 128, “Earnings Per Share.” Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares plus the dilutive effect of outstanding stock options under the Company’s equity incentive plans. Stock options outstanding that are not included in the table below because of their anti-dilutive effect for the three and nine months ended September 30, 2003 were 1,331,282 and 1,519,709, respectively. Stock options outstanding that are not included in the table below because of their anti-dilutive effect for the three and nine months ended September 30, 2002 were 1,348,600 and 766,000, respectively.

The net income and weighted average common and common equivalent shares outstanding for purposes of calculating net income per common share were computed as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2003			2002		2003		2002
Net Income (Loss)	$	(392,284	)	$	380,137	$	160,708	$	1,784,678

Weighted average number of common shares outstanding used in computing basic earnings per share		12,884,691			12,605,383		12,637,364		12,568,327

Dilutive effect of stock options outstanding		0			470,156		329,451		653,834

Weighted average shares used in computing diluted earnings per share		12,884,691			13,075,539		12,966,815		13,222,161

Basic earnings (loss) per share	$	(0.03	)	$	0.03	$	0.01	$	0.14

Diluted earnings (loss) per share	$	(0.03	)	$	0.03	$	0.01	$	0.13

4.	STOCK-BASED COMPENSATION

The Company has adopted equity incentive plans that provide for the granting of stock options to employees, directors, advisors and consultants. We account for grants of options to employees and directors under these plans applying the intrinsic value method provided for in Accounting Principles Board (“APB”) Opinion No. 25 “Accounting for Stock Issued to Employees” and related interpretations. No stock-based compensation expense is reflected in net income as all options granted under the plan had an exercise price equal to the market value of the underlying common stock on the date of the grant. In addition to APB Opinion No. 25, we provide the disclosures required by SFAS No. 123 “Accounting for Stock-Based Compensation” and by SFAS No. 148 “Accounting for Stock-Based Compensation – Transition and Disclosure.” See Note 1 for disclosure of Pro Forma Net Income and Net Income Per Share.

For purposes of determining the pro forma amounts in Note 1, the fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

	Three Months Ended September 30,		Nine Months Ended September 30,
	2003	2002	2003	2002
Risk-free interest rate	2.11% - 2.86%	2.76% - 3.62%	2.11% - 3.04%	2.76% - 4.74%
Expected dividend yield	—	—	—	—
Expected life	5 years	5 years	5 years	5 years
Expected volatility	52%	56%	52%	56%

Based upon the above assumptions, the weighted average fair value of the stock options granted for the three and nine months ended September 30, 2003 was $0.92 and $1.04, respectively. For the three and nine months ended September 30, 2002 the weighted average fair value of the stock options granted was $1.40 and $1.82, respectively. Because additional option grants are expected to be made, the above pro forma disclosures are not representative of pro forma effects on reported net income for future periods.

5.	COMPREHENSIVE INCOME

A reconciliation of comprehensive income in accordance with Statement of Financial Accounting Standards No. 130 “Reporting Comprehensive Income” is as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2003			2002		2003		2002
Net Income (Loss)	$	(392,284	)	$	380,137	$	160,708	$	1,784,678

Foreign currency translation adjustment		37,653			1,533		64,306		(13	)

Comprehensive Income (Loss)	$	(354,631	)	$	381,670	$	225,014	$	1,784,665

6.	SEGMENT INFORMATION

The Company has adopted the provisions of SFAS No. 131, “Disclosures About Segments of an Enterprise and Related Information” which establishes standards for reporting business segment information. The Company operates predominantly in the clinical research industry providing a broad range of clinical research services on a global basis to the pharmaceutical, biotechnology and medical device industries.

The following table summarizes the distribution of net revenue and contracts with significant clients:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2003			2002			2003			2002
	% of Revenues		Number of Contracts	% of Revenues		Number of Contracts	% of Revenues		Number of Contracts	% of Revenues		Number of Contracts
Client A	49	%	7	47	%	9	46	%	8	38	%	9
Client B	7	%	1	29	%	3	21	%	3	38	%	4
Client C	6	%	2	11	%	3	6	%	1	11	%	3

Top Three Clients	62	%	10	87	%	15	73	%	12	87	%	16

The following table summarizes the distribution of net revenues from external clients by geographical area:

Three Months Ended September 30,
2003					2002
U.S	Europe		Total		U.S		Europe		Total
$3,501,653	$	374,940	$	3,876,593	$	5,714,374	$	287,062	$	6,001,436

Nine Months Ended September 30,
2003					2002
U.S	Europe		Total		U.S		Europe		Total
$15,178,172	$	817,778	$	15,995,950	$	17,036,687	$	605,036	$	17,641,723

7.	LINE OF CREDIT

We maintain a demand line of credit with a bank under which maximum borrowings are the lesser of $2.5 million or 75% of eligible accounts receivable, as defined in the loan agreement, and bear interest at the LIBOR Market Index Rate plus 2.65%. As of September 30, 2003, there were no borrowings under the line of credit. The line of credit was renewed on June 17, 2003 and expires on June 30, 2004. Borrowings under the line of credit are secured by substantially all of our assets. Our agreement with the bank provides that we maintain a minimum tangible net worth of $10.75 million and a ratio of total liabilities to tangible net worth of not more than 1.25 to 1.00. As of September 30, 2003, we were in compliance with these covenants.

8.	OTHER LIABILITIES

As of January 1, 2003, the Company increased by approximately 12,700 to 34,000 the amount of square feet under lease in the same building. The term of the lease was also extended to 2010 and monthly lease payments increased from $50 thousand to $72 thousand. As an incentive for the Company to acquire the additional space, the lessor granted the Company $814 thousand in lease incentives that were used to pay for architectural fees, renovations and improvement costs for the new space. The lease incentives were capitalized as if the Company incurred the costs to make the improvements and are included in Property and Equipment. These assets and the related liability are amortized over the remaining life of the lease at a rate of approximately $116 thousand per year as an additional amortization expense and a reduction in rent expense, respectively. The accounting for these lease incentives has no impact on net income, stockholders’ equity or cash flow.

9.	SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid for income taxes for the three and nine months ended September 30, 2003 was approximately $91 thousand and $1.0 million, respectively. For the three and nine months ended September 30, 2002, cash paid for income taxes was approximately $72 thousand and $1.7 million, respectively. Cash interest income for the three and nine months ended September 30, 2003 was approximately $2 thousand and $8 thousand, respectively. For the three and nine months ended September 30, 2002, net cash interest expense was approximately $0 and $3

thousand, respectively. We entered into capital lease obligations totaling $0 and $139 thousand during the three and nine months ended September 30, 2003, respectively. During the three and nine months ended September 30, 2002, we did not enter into any new capital leases. The acquisition of property and equipment through lease incentives totaled $0 and $814 thousand during the three and nine months ended September 30, 2003, respectively. During the three and nine months ended September 30, 2002, there were no acquisitions of property and equipment through lease incentives.

10.

EXERCISE OF EMPLOYEE STOCK OPTION

On July 31, 2003, Dr. Borow, President and Chief Executive Officer of Covalent, exercised an employee stock option to acquire 500,000 shares of Covalent common stock. The option had a grant date of August 6, 1998, an expiration date of August 5, 2003 and an exercise price of $0.6875. As payment for the shares issued and related withholding taxes, the Company received from Dr. Borow 140,432 Covalent common shares that were owned by him. The shares received by the Company are included as treasury stock in our Consolidated Balance Sheet at September 30, 2003.

11.

INCOME TAX BENEFIT

For the three months ended September 30, 2003, the Company recorded an income tax benefit of $593 thousand. Included in the income tax benefit was $495 thousand attributed to a loss from operations generated in the U.S. and $98 thousand from the reversal of a prior year deferred tax credit. Also impacting the amount of the income tax benefit was the utilization of approximately $77 thousand in tax loss carryforwards on earnings generated from outside the U.S.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

The following discussion and analysis should be read in conjunction with the Company’s Annual Report on Form 10-KSB, as well as the Company’s financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. When used in this Report on Form 10-Q and in other public statements, both oral and written, by the Company and Company officers, the words “estimate,” “project,” “expect,” “intend,” “believe,” “anticipate” and similar expressions are intended to identify forward-looking statements regarding events and trends that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Such factors include, among others: (i) our success in attracting new business and retaining existing clients and projects; (ii) the size, duration and timing of clinical trials; (iii) the termination, delay or cancellation of clinical trials; (iv) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (v) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vi) the ability to maintain profit margins in a competitive marketplace; (vii) our ability to attract and retain qualified personnel; (viii) the sensitivity of our business to general economic conditions; and (ix) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. These and other factors that could cause the forward looking statements to be materially different are described in greater detail in our Annual Report on Form 10-KSB in the section entitled “Risk Factors that Might Affect our Business or Stock Price.”

Company Overview

In this discussion, the terms “Company,” “we,” “us” and “our” refer to Covalent Group, Inc. and our subsidiaries, except where it is made clear otherwise.

We are a clinical research organization (“CRO”) which is a leader in the design and management of complex clinical trials for the pharmaceutical, biotechnology and medical device industries. Our mission is to provide our clients with high quality, full-service support for their clinical trials. We offer therapeutic expertise, experienced team management and advanced technologies. Our headquarters is in Wayne, Pennsylvania and our International operations are based in Guildford, Surrey, United Kingdom.

Our clients consist of many of the largest companies in the pharmaceutical, biotechnology and medical device industries. From protocol design and clinical program development, to proven patient recruitment, to managing the regulatory approval process, we have the resources to directly implement or manage Phase I through IV clinical trials and to deliver clinical programs on time and within budget. We have clinical trial experience across a wide variety of therapeutic areas, such as cardiovascular, endocrinology/metabolism, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, womens’ health and respiratory medicine. We have the capacity and expertise to conduct clinical trials on a global basis. We have managed studies in 20 countries, including the United States, Canada, Western and Eastern Europe, the Middle East, South Africa, Australia and Scandinavia.

We were incorporated in August 1998 in Nevada and in June 2002, we changed our state of incorporation to Delaware.

General

The information set forth and discussed below for the three and nine months ended September 30, 2003 and 2002 is derived from the Financial Statements included elsewhere herein. The financial information set forth and discussed below is unaudited but, in the opinion of management, reflects all adjustments (primarily consisting of normal recurring adjustments) necessary for a fair presentation of such information. The results of our operations for a particular quarter may not be indicative of results expected during the other quarters or for the entire year.

Our quarterly results can fluctuate as a result of a number of factors, including our success in attracting new business, the size and duration of clinical trials, the timing of client decisions to conduct new clinical trials or to cancel or delay ongoing trials, and other factors, many of which are beyond our control.

Net revenue is derived principally from the design, management and monitoring of clinical research studies. Clinical research service contracts generally have terms ranging from several months to several years. A portion of the contract fee is generally payable upon execution of the contract, with the balance payable in installments over the life of the contract. The majority of our net revenue is recognized from fixed-price contracts on a proportional performance basis. To measure the performance, we compare actual direct costs incurred to estimated total contract direct costs, which is the best indicator of the performance of the contract obligations as the costs relate to the labor hours incurred to perform the service.

Contracts generally may be terminated by clients immediately or with short notice. Clinical trials may be terminated or delayed for several reasons, including, among others, unexpected results or adverse patient reactions to the drug, inadequate patient enrollment or investigator recruitment, manufacturing problems resulting in shortages of the drug or decisions by the client to de-emphasize or terminate a particular trial or development efforts on a particular drug. Depending on the size of the trial in question, a client’s decision to terminate or delay a trial in which we participate could have a material and adverse effect on our backlog, future revenue and results from operations.

Our backlog was approximately $14 million as of September 30, 2003 as compared to approximately $20 million as of September 30, 2002. Our backlog consists of anticipated net revenue from signed contracts, letters of intent and certain verbal commitments that either have not started but are anticipated to begin in the near future or are in process and have not yet been completed. Many of our studies and projects are performed over an extended period of time, which may be several years. Amounts included in backlog have not yet been recognized as net revenue in our Consolidated Statements of Operations. Once contracted work begins, net revenue is recognized over the life of the contract on a proportional performance basis. The recognition of net revenue and contract terminations, if any, reduces our backlog while the awarding of new business increases our backlog. For the nine months ended September 30, 2003, we obtained approximately $11.3 million of new business awards as compared to approximately $12 million for the nine months ended September 30, 2002.

We believe that our backlog as of any date may not necessarily be a meaningful predictor of future results because backlog can be affected by a number of factors including the size and duration of contracts, many of which are performed over several years. Additionally, contracts relating to our clinical trial business may be subject to early termination by the client or delay for many reasons, as described above. Also, the scope of a contract can change during the course of a study. For these reasons, we might not be able to fully realize our entire backlog as net revenue.

The following table sets forth amounts for certain items in our consolidated statements of operations expressed as a percentage of net revenue. The following table excludes revenue and costs related to reimbursable out-of-pocket expenses because they are not generated by the services we provide, do not yield any gross profit to us, and do not have any impact on our net income. We believe this information is useful to our investors because it presents the net revenue and expenses that are directly attributable to the services we provide to our clients and provides a more accurate picture of our operating results and margins.

Percentage of Net Revenue, Excluding Reimbursable Out-of-Pocket Expenses

	Three Months Ended September 30				Nine Months Ended September 30
	2003		2002		2003		2002
	(Unaudited)				(Unaudited)
Net revenue	100.0	%	100.0	%	100.0	%	100.0	%
Operating Expenses
Direct	88.6	%	70.6	%	70.1	%	60.7	%
Selling, general and administrative	30.9	%	17.0	%	26.2	%	20.3	%
Depreciation	6.0	%	2.8	%	4.2	%	2.6	%
Income (Loss) from Operations	-25.5	%	9.6	%	-0.4	%	16.4	%
Net Income (Loss)	-10.1	%	6.3	%	1.0	%	10.1	%

Critical Accounting Policies and Estimates

The following discussion should be read in conjunction with the consolidated financial statements and notes thereto.

Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. On an ongoing basis, management evaluates its judgments and estimates. Management bases its judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Management considers the following policies to be most critical in understanding the more complex judgments that are involved in preparing our consolidated financial statements and the uncertainties that could affect our results of operations and financial condition.

Revenue Recognition

The majority of our net revenue is recognized from fixed-price contracts on a proportional performance basis. To measure the performance, we compare actual direct costs incurred to estimated total contract direct costs, which is the best indicator of the performance of the contract obligations as the costs relate to the labor hours incurred to perform the service. Total direct costs are incurred for each contract and compared to estimated total direct costs for each contract to determine the percentage of the contract that is completed. This percentage is multiplied by the estimated total contract value to determine the amount of net revenue recognized. A formal project review process takes place quarterly although most projects are evaluated on an ongoing basis. Management reviews the estimated total direct costs on each contract to determine if estimated amounts are correct, and estimates are adjusted as needed. If we determine that a loss will result from the performance of a fixed-price contract, the entire amount of the estimated loss is charged against income in the period in which such determination is made. Because of the inherent uncertainties in estimating direct costs required to complete a project, particularly complex, multi-year studies, it is possible that the estimates used will change and could result in a material change to our estimates. Original estimates might also be changed due to changes in the scope of work. We attempt to negotiate contract amendments with the client to cover these services provided outside the terms of the original contract. There can be no assurance that the client will agree to the proposed amendments, and we ultimately bear the risk of cost overruns. For terminated studies, our contracts frequently entitle us to receive the costs of winding down the terminated project, as well as all fees earned by us up to the time of termination. Some contracts also entitle us to an early termination fee, usually in the form of a predetermined fee or percentage of revenue expected to be earned for completion of the project.

Reimbursable Out-of-Pocket Expenses

Concentration of Credit Risk

Our accounts receivable and costs and estimated earnings in excess of related billings on uncompleted contracts are concentrated with a small number of companies within the pharmaceutical, biotechnology and medical device industries. The significant majority of this exposure is to large, well established firms. Credit losses have historically been minimal. As of September 30, 2003, the total of accounts receivable and costs and estimated earnings in excess of related billings on uncompleted contracts was $16.0 million. Of this amount, the exposure to our three largest clients was 67% of the total, with the three largest clients representing 31%, 24%, and 12% of total exposure, respectively. As of September 30, 2002, the total of accounts receivable and costs and estimated earnings in excess of related billings on uncompleted contracts was $15.9 million. Of this amount, the exposure to our three largest clients was 95% of the total, with the three largest clients representing 56%, 28%, and 11% of total exposure, respectively.

Operating Expenses

Direct expenses include amounts incurred during the period that are directly related to the management or completion of a clinical trial or related project and generally include direct labor and related benefit charges, other direct costs and certain allocated expenses. Direct costs as a percentage of net revenues tend to fluctuate from one period to another as a result of changes in the mix of services provided and the various studies conducted during any time period. Selling, general and administrative expenses include the salaries, wages and benefits of all administrative, finance and business development personnel, and all other support expenses not directly related to specific contracts.

Stock-Based Compensation

Statement of Financial Accounting Standards (“SFAS”) No. 123 “Accounting for Stock-Based Compensation” and by SFAS No. 148 “Accounting for Stock-Based Compensation – Transition and Disclosure.”

Three Months Ended September 30, 2003 Compared with the Three Months Ended September 30, 2002

Net revenue for the three months ended September 30, 2003 decreased 35% to $3.9 million as compared to $6.0 million for the three months ended September 30, 2002. The decrease of $2.1 million reflects a lower than anticipated level of new business awards as well as the fact that several projects were winding down as they enter the later stages of their development schedules. Also reducing revenues were increases to the estimated costs to complete several projects. New business awards and changes of scope for the three months ended September 30, 2003 were approximately $2.2 million as compared to approximately $1.2 for the three months ended September 30, 2002. If we are not able to increase our level of new business production, our business, financial condition and results of operations will be materially and adversely affected. For the three months ended September 30, 2003, net revenue from our three largest clients amounted to 62% of our net revenue, with the three largest clients representing 49%, 7%, and 6% of net revenue, respectively. For the three months ended September 30, 2002, net revenue from our three largest clients amounted to 87% of our net revenue, with the three largest clients representing 47%, 29%, and 11% of net revenue, respectively.

Reimbursement revenue consisted of reimbursable out-of-pocket expenses incurred on behalf of our clients. Reimbursements are made at cost, without mark-up or profit, and therefore have no impact on net income.

Direct expenses included compensation and other expenses directly related to conducting clinical studies. These costs decreased by $802 thousand to $3.4 million for the three months ended September 30, 2003 from $4.2 million for the three months ended September 30, 2002. The decrease in direct expenses resulted principally from a decline in personnel costs associated with lower project requirements and other cost control initiatives. Direct expenses as a percentage of net revenue were 88.6% for the three months ended September 30, 2003 as compared to 70.6% for the three months ended September 30, 2002. The increase in the ratio was principally due to the lower level of net revenue reported for the quarter.

Selling, general, and administrative expenses included the salaries, wages and benefits of all administrative, financial and business development personnel and all other support expenses not directly related to specific contracts. Selling, general and administrative expenses for the three months ended September 30, 2003 were $1.2 million, or 30.9% of net revenue, as compared to $1.0 million, or 17.0% of net revenue, for the three months ended September 30, 2002. The increase of $176 thousand primarily reflects increased rent and insurance expense. The increase as a percentage of net revenue generally reflects the impact of increased rent and insurance expense and a lower level of net revenue.

Depreciation and amortization expense increased to $232 thousand for the three months ended September 30, 2003 from $171 thousand for the three months ended September 30, 2002, primarily as a result of additional leasehold improvements.

Income from operations decreased by $1.6 million to a loss from operations of $988 thousand, primarily for the reasons noted in the preceding paragraphs.

Net interest income for the three months ended September 30, 2003 was $2 thousand which was comparable to the three months ended September 30, 2002.

The effective income tax rate (benefit) for the three months ended September 30, 2003 and 2002 was (60)% and 34%, respectively. The 2003 credit rate reflects a loss from operations in the U.S., positive earnings from outside the United States that still benefit from the utilization of a tax loss carryforward, and the reversal of a prior year deferred tax credit in the amount of $98 thousand.

The net loss for the three months ended September 30, 2003 was $392 thousand, or $0.03 per diluted share, as compared to net income of $380 thousand, or $0.03 per diluted share for the three months ended September 30, 2002, primarily for the reasons noted above.

Nine Months Ended September 30, 2003 Compared with the Nine Months Ended September 30, 2002

Net revenue for the nine months ended September 30, 2003 decreased 9% to $16.0 million as compared to $17.6 million for the nine months ended September 30, 2002. The decrease in net revenue was a result of a lower than anticipated level of new business awards as well as the fact that several projects were winding down as they enter the later stages of their development schedules. Also reducing revenues were increases to the cost to complete estimates on several projects. New business awards and changes of scope for the nine months ended September 30, 2003 were approximately $11 million as compared to approximately $12 million for the nine months ended September 30, 2002. If we are not able to increase our level of new business production, our business, financial condition and results of operations will be materially and adversely affected. For the nine months ended September 30, 2003, net revenue from our three largest clients amounted to 73% of our net revenue, with the three largest clients representing 46%, 21%, and 6% of net revenue, respectively. For the nine months ended September 30, 2002, net revenue from our three largest clients amounted to 87% of our net revenue, with the three largest clients representing 38%, 38%, and 11% of net revenue, respectively.

Direct expenses included compensation and other expenses directly related to conducting clinical studies. These costs increased by $502 thousand to $11.2 million for the nine months ended September 30, 2003 from $10.7 million for the nine months ended September 30, 2002. The increase in direct expenses resulted principally from the increase in personnel costs associated with increased project requirements, largely in the first quarter of 2003. Direct expenses as a percentage of net revenue were 70.1% for the nine months ended September 30, 2003 as compared to 60.7% for the nine months ended September 30, 2002. The increase in the ratio was principally due to the lower level of net revenue reported during 2003.

Selling, general, and administrative expenses included the salaries, wages and benefits of all administrative, financial and business development personnel and all other support expenses not directly related to specific contracts. Selling, general and administrative expenses for the nine months ended September 30, 2003 were $4.2 million, or 26.2% of net revenue, as compared to $3.6 million, or 20.3% of net revenue, for the nine months ended September 30, 2002. The increase of $610 thousand primarily reflects increased staff in early 2003 as well as higher rent and insurance expense. The increase as a percentage of net revenue generally reflects the impact of increased rent and insurance expense against a lower level of net revenue.

Depreciation and amortization expense increased to $667 thousand for the nine months ended September 30, 2003 from $461 thousand for the nine months ended September 30, 2002, primarily as a result of additional leasehold improvements.

Income from operations decreased by $3.0 million, to a loss from operations of $70 thousand, primarily for the reasons noted in the preceding paragraphs.

Net interest income for the nine months ended September 30, 2003 was $9 thousand compared to net interest income of $6 thousand for the nine months ended September 30, 2002, largely the result of having more cash to invest.

The effective income tax rate (benefit) for the nine months ended September 30, 2003 and 2002 was (361)% and 39%, respectively. The 2003 credit rate reflects a loss from operations in the U.S., positive earnings from outside the United States that still benefit from the utilization of a tax loss carryforward, and the reversal of a prior year deferred tax credit in the amount of $98 thousand.

Net income for the nine months ended September 30, 2003 decreased to $161 thousand, or $0.01 per diluted share, as compared to $1.8 million, or $0.13 per diluted share for the nine months ended September 30, 2002, primarily for the reasons noted above.

Liquidity and Capital Resources

The clinical research organization industry is generally not considered capital intensive. We expect to continue to fund our operations from existing cash resources, cash flow from operations and borrowings under our line of credit. We expect that our principal cash requirements on both a short and long-term basis will be for the funding of our operations and capital expenditures. We expect to continue expanding our operations through internal growth, expansion of our existing services, continued expansion of our international operational capabilities, and the development of new products and services for the pharmaceutical, biotechnology and medical device industries. We believe that our existing cash resources, cash generated from operations, and the borrowing availability under our line of credit will provide sufficient liquidity for the foreseeable future. However, in the event that we make significant acquisitions in the future, we may need to raise additional funds through additional borrowings or the issuance of debt or equity securities.

Our contracts usually require a portion of the contract amount to be paid at the time the contract is initiated. Additional payments are generally made upon completion of negotiated performance milestones, or on a regularly scheduled basis, throughout the life of the contract. Accordingly, cash receipts do not necessarily correspond to costs incurred and revenue recognized. For terminated studies, our contracts frequently entitle us to receive the costs of winding down the terminated project, as well as all fees earned by us up to the time of termination. Some contracts also entitle us to an early termination fee, usually in the form of a predetermined fee or percentage of revenue expected to be earned for completion of the project.

Net revenue is recognized on a proportional performance basis. We typically receive a low volume of large-dollar receipts. As a result, the number of days net revenue outstanding in accounts receivable, costs and estimated earnings in excess of related billings, customer advances, and billings in excess of related costs will fluctuate due to the timing and size of billings and cash receipts. At September 30, 2003, the net days revenue outstanding was 227 days compared to 130 days at December 31, 2002.

Compared to December 31, 2002, accounts receivable increased $668 thousand to $8.3 million at September 30, 2003, primarily due to the timing of billings and progress payments for clinical trials. Of the accounts receivable balance at September 30, 2003, less than 4% of the total was over 60 days past invoice date.

Compared to December 31, 2002, costs and estimated earnings in excess of related billings on uncompleted contracts decreased $1.3 million to $7.8 million at September 30, 2003. The decrease primarily represents timing differences between the net revenue recognized on the trials being managed and the billing milestones or payment schedules contained in the contracts with our clients. The balance at September 30, 2003 primarily consisted of 4 clinical trials, which individually constituted 39%, 15%, 13% and 6% of the balance. These clinical trials are expected to be completed during 2003 and 2004. The decrease in the liability account billings in excess of related costs and estimated earnings on uncompleted contracts of $425 thousand to $1.4 million as of September 30, 2003 from $1.8 million as of December 31, 2002, resulted from continued progress on several contracts with billing schedules weighted toward the earlier phases of the study. The increase in customer advances of $796 thousand to $4.4 million as of September 30, 2003 from $3.6 million as of December 31, 2002, primarily reflected the advance billing for investigator fees involving a study that began during the most recent quarter.

Our net cash provided by operating activities was $735 thousand for the nine months ended September 30, 2003, compared with net cash used by operating activities of $1.8 million for the nine months ended September 30, 2002. The primary factor underlying this change was the decrease in our costs and estimated earnings in excess of related billings on uncompleted contracts relative to the end of the prior year. Net cash used by investing activities, consisting principally of purchases of property, equipment and leasehold improvements, was $764 thousand for the nine months ended September 30, 2003, compared with net cash used by investing activities of $344 thousand for the nine months ended September 30, 2002. Purchases and leasehold improvements for the nine months ended September 30, 2003 included leasehold improvements, software and hardware, including host servers and computers for our corporate office and field-based personnel. Net cash provided by financing activities was $126 thousand for the nine months ended September 30, 2003, compared with net cash provided by financing activities of $320 thousand for the nine months ended September 30, 2002. The primary difference related to the scheduled repayment of capital lease obligations and the exercise of employee stock options. During the quarter, 140,432 shares of common stock were taken into treasury in connection with the exercise of an employee stock option.

As a result of these cash flows, our cash and cash equivalents balance at September 30, 2003 was $2.3 million as compared to $2.1 million at December 31, 2002.

We purchased equipment and made leasehold improvements of $764 thousand during the nine months ended September 30, 2003. We anticipate capital expenditures of approximately $25 - $50 thousand during the remainder of 2003, primarily for leasehold improvements, software applications, workstations, personal computer equipment and related assets.

Recently Issued Accounting Standards

contracts (collectively referred to as derivatives) and for hedging activities under SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003, except as stated below and for hedging relationships designated after June 30, 2003. The provisions of SFAS No. 149 that relate to Statement 133 Implementation Issues that have been effective for fiscal quarters that began prior to June 15, 2003, should continue to be applied in accordance with their respective effective dates. The Company has not entered into any derivative transactions and therefore this standard is not expected to have a material impact on our financial statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Market Risk

The fair value of cash and cash equivalents, restricted cash, accounts receivable, costs and estimated earnings in excess of related billings on uncompleted contracts, accounts payable, accrued expenses and billings in excess of related costs and estimated earnings on uncompleted contracts are not materially different than their carrying amounts as reported at September 30, 2003 and September 30, 2002.

As of September 30, 2003, the Company was not a counterparty to any forward foreign exchange contracts or any other transaction involving a derivative financial instrument.

Foreign Currency Exchange Risk

The Company is exposed to foreign currency exchange risk through its international operations. For the three and nine months ended September 30, 2003, approximately 10% and 5%, respectively, of our net revenues were derived from contracts denominated in other than U.S. Dollars. Our financial statements are denominated in U.S. Dollars. As a result, factors associated with international operations, including changes in foreign currency exchange rates, could affect our results of operations and financial condition. Contracts entered into in the United States are denominated in U.S. Dollars. Contracts entered into by our international subsidiary are generally denominated in pounds sterling or Euros. To date, we have not engaged in any derivative or contractual hedging activities related to our foreign exchange exposures. We believe that these exposures are limited by virtue of their size relative to our overall operations as well as the partial natural hedge afforded by our local currency expenditures to service these local currency contracts.

Assets and liabilities of the Company’s international operations are translated into U.S. Dollars at exchange rates in effect on the balance sheet date and equity accounts are translated at historical exchange rates. Revenue and expense items are translated at average exchange rates in effect during

the quarter. Gains or losses from translating foreign currency financial statements are recorded in other comprehensive income. The cumulative translation adjustment included in other comprehensive income for the three months ended September 30, 2003 and September 30, 2002 was $38 thousand and $2 thousand, respectively. For the nine months ended September 30, 2003 and September 30, 2002, the cumulative translation adjustment included in other comprehensive income was $64 thousand and $0 thousand, respectively.

Inflation

We believe that the effects of inflation generally do not have a material adverse impact on our operations or financial condition.

ITEM 4.

CONTROLS AND PROCEDURES

(a)

An evaluation was performed under the supervision and with the participation of the Company’s management, including its Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, of the effectiveness of the Company’s disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of September 30, 2003. Based upon that evaluation, the Company’s management, including the CEO and CFO, concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported as specified in the Securities and Exchange Commission rules and forms.

(b)	There were no significant changes in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 6.

EXHIBITS AND REPORTS ON FORM 8-K

(a)

Exhibits

10.1

Employment Agreement between Covalent Group, Inc. and Brian Dickson, M.D.

31.1

Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b)

Form 8-K

None.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COVALENT GROUP, INC.

Dated: November 13, 2003	By:	/s/ Kenneth M. Borow, M.D.
		Kenneth M. Borow, M.D.
		President and Chief Executive Officer

Dated: November 13, 2003	By:	/s/ Jorge A. Leon
		Jorge A. Leon
		Chief Operating Officer and
		Chief Financial Officer

EXHIBIT INDEX

Exhibit		Description

10.1		Employment Agreement between Covalent Group, Inc. and Brian Dickson, M.D.

31.1		Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents